Omalizumab Discontinuation in Chronic Spontaneous Urticaria: Effectiveness and Predictors of Response and Relapse Comparing Abrupt Cessation and Dose Spacing in a Retrospective Real-Life Study.

Xolair (omalizumab) - Roche, Novartis

http://www.ncbi.nlm.nih.gov/pubmed/42786691

Astrid Lappi; Federica Sardanelli; François Rosset; Giovanni Cavaliere; Luca Mastorino; Matteo Brizio; Nadia Sciamarrelli; Paolo Borrelli; Pietro Quaglino; Silvia Borriello; Simone Ribero; Sophie Frassy

Sep 26, 2026